Redefining adjuvant chemotherapy in patients with stage III colon cancer: X-ACT trial

References

• Twelves C, Wong A, Nowacki MP et al. Capecitabine as adjuvant treatment for stage III colon cancer. N. Engl. J. Med.352(26), 2696–2704 (2005).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Dicato M, Wils J et al. Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, Ireland, 2001). Eur. J. Cancer38(11), 1429–1436 (2002).
   PubMedGoogle Scholar
• Moertel CG, Fleming TR, Macdonald JS et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N. Engl. J. Med.322(6), 352–358 (1990).
   PubMed Web of Science ®Google Scholar
• Moertel CG, Fleming TR, Macdonald JS et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes’B2 colon cancer. J. Clin. Oncol.13(12), 2936–2943 (1995).
   PubMed Web of Science ®Google Scholar
• No authors listed. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet.345(8955), 939–944 (1995).
   Google Scholar
• O’Connell MJ, Mailliard JA, Kahn MJ et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J. Clin. Oncol.15(1), 246–250 (1997).
   PubMed Web of Science ®Google Scholar
• Wolmark N, Rockette H, Fisher B et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J. Clin. Oncol.11(10), 1879–1887 (1993).
   PubMed Web of Science ®Google Scholar
• Porschen R, Bermann A, Loffler T et al. Fluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected stage III colon cancer: results of the trial adjCCA-01. J. Clin. Oncol.19(6), 1787–1794 (2001).
   PubMedGoogle Scholar
• Miwa M, Ura M, Nishida M et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur. J. Cancer34(8), 1274–1281 (1998).
   PubMed Web of Science ®Google Scholar
• Twelves C. Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, Phase III trials. Eur. J. Cancer38(Suppl.2), 15–20 (2002).
   PubMed Web of Science ®Google Scholar
• Cassidy J, Twelves C, Van Cutsem E et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann. Oncol.13(4), 566–575 (2002).
   PubMed Web of Science ®Google Scholar
• Borner MM, Schoffski P, de Wit R et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur. J. Cancer38(3), 349–358 (2002).
   PubMed Web of Science ®Google Scholar
• Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J. Clin. Oncol.15(1), 110–115 (1997).
   PubMed Web of Science ®Google Scholar
• Payne SA. A study of quality of life in cancer patients receiving palliative chemotherapy. Soc. Sci. Med.35(12), 1505–1509 (1992).
   PubMed Web of Science ®Google Scholar
• Scheithauer W, McKendrick J, Begbie S et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann. Oncol.14(12), 1735–1743 (2003).
   PubMed Web of Science ®Google Scholar
• Twelves C, Scheithauer W, McKendrick J et al. 5-year overall survival update from the X-ACT trial of capecitabine vs 5-FU/LV as adjuvant treatment for stage III colon cancer. Eur. J. Cancer Suppl.5(6), (2007) (Abstract 1LB).
   Google Scholar
• Cassidy J, Douillard JY, Twelves C et al. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes’C colon cancer: the X-ACT trial. Br. J. Cancer94(8), 1122–1129 (2006).
   PubMed Web of Science ®Google Scholar
• Garrison L, Patel KK, Sengupta N et al. The cost–effectiveness of capecitabine as adjuvant oral chemotherapy for Dukes’C cancer. Presented at:International Society for Pharmacoeconomics and Outcomes Research Annual International Meeting. Washington, DC, USA, 15–18 May 2005 (Poster PCN7).
   Google Scholar
• Di Costanzo F, Sobrero A, Twelves C et al. Capecitabine vs bolus 5-FU/LV as adjuvant chemotherapy for patients with Dukes’C colon cancer: economic evaluation in an Italian hospital setting. J. Clin. Oncol.24(Suppl.18), (2006) (Abstract 13518).
   Google Scholar
• Dufour PR, Douillard J, Ychou M et al. Cost-effectiveness of adjuvant capecitabine, Mayo Clinic and de Gramont regimens for stage III colon cancer in the French setting. J. Clin. Oncol.24(Suppl.18), (2006) (Abstract 13506).
   Google Scholar
• Cortes P, Douillard J-Y, Twelves C et al. Pharmacoeconomic analysis of capecitabine in the adjuvant setting. Preliminary cost analysis in Portugal based on results from the X-ACT trial comparing capecitabine with 5-FU/LV in patients with Dukes’C colon cancer. Presented at: Portuguese Conference on Health Economy 2005. Coimbra, Portugal, 24–26 Nov 2005 (Poster).
   Google Scholar
• Virik K, Skedgel C, Younis T. Economic evaluation of adjuvant chemotherapy in stage III (SIII) colon cancer: capecitabine versus 5FU/LV. J. Clin. Oncol.24(Suppl.18) (2006) (Abstract 6046).
   Google Scholar
• Lembersky BC, Wieand HS, Petrelli NJ et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J. Clin. Oncol.24(13), 2059–2064 (2006).
   PubMed Web of Science ®Google Scholar
• Andre T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med.350(23), 2343–2351 (2004).
   PubMed Web of Science ®Google Scholar
• Kuebler JP, Wieand HS, O’Connell MJ et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J. Clin. Oncol.25(16), 2198–2204 (2007).
   PubMed Web of Science ®Google Scholar
• Schmoll HJ, Cartwright T, Tabernero J et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J. Clin. Oncol.25(1), 102–109 (2007).
   PubMed Web of Science ®Google Scholar
• Cassidy J, Clarke S, Rubio ED et al. First efficacy and safety results from XELOX-1/NO16966, a randomised 2×2 factorial phase III trial of XELOX vs. FOLFOX4 + bevacizumab or placebo in first-line metastatic colorectal cancer (MCRC). Ann. Oncol.17(Suppl. 9), (2006) (Abstract LBA3).
   Google Scholar